CVS Health (NYSE:CVS) Q4 2025 Earnings call February 10, 2026 08:00 AM ET Speaker7Hello and welcome to CVS Health's fourth quarter 2025 earnings call. We ask that you please hold all questions until the end of the prepared remarks, at which time you will be given instructions for the question-and-answer session. As a reminder, this conference is being recorded today. If you have any objections, please disconnect at this time. I would now like to pass the call to Larry McGrath, Chief Strategy Officer. Larry, ...

DALLAS--(BUSINESS WIRE)--Elara Caring (Elara), a leading national provider of skilled home health, hospice, behavioral health, and personal care services, today announced that it has entered into an agreement for a strategic investment from Ares' Private Equity Group (Ares) and DaVita. The investment is intended to expand access to personalized, clinically advanced care at home for patients with complex and acute needs. Elara will continue to operate as a wholly independent company led by CEO Ananth Mohan a ...

Core Insights - UnitedHealth Group's Optum health services is undergoing a strategic turnaround, which includes exiting certain markets and terminating contracts with misaligned medical care providers [2][4] - The company aims to enhance its value-based care model to ensure patients receive appropriate care at the right time and cost [4][5] Financial Performance - UnitedHealth's fourth quarter net income fell to $10 million, a significant drop from $5.5 billion year-over-year, while full-year net income decreased to $12 billion from $14.4 billion [6] - Optum's revenues increased by 8% in Q4 to $70.3 billion and by 7% for the year to $270.6 billion, compared to $253 billion in 2024 [6] - However, Optum Health's full-year revenues declined by 3% to $102 billion, with adjusted earnings from operations dropping to $2.3 billion from $7.9 billion in 2024 [7] Strategic Focus - Optum plans to achieve approximately 9% operating earnings growth in 2026 by concentrating on integrated value-based care [8] - The company will reduce its affiliated network by nearly 20% to better align physicians and services [8] - Optum will eliminate unaligned PPO contracts and reposition certain markets to enhance operational efficiency [8] Technological Advancements - The company is pushing its medical care providers to adopt advanced technology and artificial intelligence to improve care delivery [8] - Nearly 100% of employed provider groups are now using one of three strategic electronic medical records systems, down from 18, facilitating better data management and workflow [9]

Financial Performance & Guidance - Aveanna's 2025 revenue guidance is in the range of $2425 million to $2445 million[14, 63] - The adjusted EBITDA guidance for 2025 is $318 million to $322 million[14, 63] - The company projects 2026 revenue in the range of $2540 million to $2560 million[70] - The adjusted EBITDA guidance for 2026 is $318 million to $322 million[70] - Q3 2025 revenue was $621.9 million, a 22.2% increase year-over-year[53] - Q3 2025 adjusted EBITDA was $80.1 million, a 67.5% increase year-over-year[53] Segment Performance - Private Duty Services (PDS) revenue for 2025 is $1947 million[28] - Home Health & Hospice (HHH) revenue for 2025 is $239 million[34] - Medical Solutions (MS) revenue for 2025 is $175 million[43] Key Operating Statistics - Aveanna has 366 locations across 38 states[14] - The company employs approximately 29,000 caregivers[14] - Aveanna delivers approximately 45 million homecare hours annually[14]

Core Viewpoint - Humana Inc. (HUM) is at a critical juncture as rising medical costs and Medicare Advantage (MA) challenges have impacted investor sentiment, raising the question of whether the worst is already priced in [1] Performance Summary - Over the past year, HUM shares have increased by 1.8%, outperforming the broader industry which saw a decline of 28.3%, and also faring better than peers like UnitedHealth Group (UNH) and Centene Corporation (CNC), which fell by 35% and 32.6% respectively [2][8] - Despite ongoing volatility, the relative strength of HUM suggests that investors are not ready to abandon the stock [2] Near-Term Pressures - Humana is experiencing pressure from elevated medical costs, particularly in its Medicare Advantage segment, with higher utilization trends and inpatient admissions affecting its medical care ratio [6][8] - Regulatory uncertainty regarding MA reimbursement rates continues to be a concern, limiting potential upside in the near term [6] Long-Term Tailwinds - Humana's long-term investment case is supported by its scale, the aging U.S. population, and initiatives focused on value-based care [9] - The company remains a leading Medicare Advantage provider with strong brand recognition and an integrated care delivery platform [9] Valuation Insights - Humana's current forward 12-month P/E ratio is 21.26X, which is above its five-year median of 17.69X and the industry average of 15.63X [10] - The stock is priced below the average analyst target of $284.87, indicating a potential upside of about 10% [11] Earnings Estimates - The Zacks Consensus Estimate for HUM's 2025 EPS is $17.08, reflecting a year-over-year growth of 5.4%, while revenues are expected to increase by 10% to $128.94 billion [12] Conclusion - Humana lacks a clear catalyst for immediate recovery, but the stock's recent sell-off may have already accounted for much of the operational and regulatory risks [13] - For current investors, maintaining positions may be the most rational strategy, while new investors are advised to monitor cost trends and reimbursement clarity before entering [14]

Summary of Agilon Health FY Conference Call (December 02, 2025) Company Overview - **Company**: Agilon Health (NYSE: AGL) - **Industry**: Healthcare Services, specifically focused on Medicare Advantage and value-based care models Key Points and Arguments Business Transition and Contracting Cycle - The company is undergoing a long-cycle business transition, with 50% of contracts open for the year, many being multi-year contracts [4][3] - Improvements made in the current year will not impact the profit and loss statement until the following year, indicating a longer economic cycle in the industry [4][3] Contracting Strategy - Agilon Health has focused on achieving appropriate economics for the value delivered to payer partners, with a disciplined approach to contracting [5][5] - In 2024, 60% of contracts included Part D risk, which is expected to decrease to 30% in 2025, with further improvements anticipated in 2026 [5][5] - The company is removing elements from contracts that introduce variability, such as Part D and supplemental benefits [6][6] Quality and Risk Adjustment - The company has a $25 million opportunity for quality performance in 2025, which is expected to double in 2026 [14][14] - Agilon is focusing on STAR scores, which have a long delay but are crucial for quality performance and financial incentives [14][14] Regulatory Landscape and Risk Management - The company is actively narrowing the risks it takes on, particularly concerning items outside its control, such as Part D and supplemental benefits [13][13] - Agilon has implemented a data pipeline to improve visibility into member-level premiums and costs, aiding in managing regulatory changes [16][16] Financial Outlook - The company expects to end 2025 with $300 million in cash and $100 million by the end of 2026, indicating good visibility into cash flow based on 2025 performance [66][66] - The benchmark rate for Medicare Advantage is expected to increase by approximately 9%, which is seen as a tailwind for the company [33][33] Market Dynamics and Growth Strategy - Agilon has paused growth initiatives for 2025 and 2026 to focus on improving profitability, despite strong demand from primary care partners [30][30] - The company has exited markets that do not present a near-term path to profitability, affecting approximately 29,000 members [30][30] Physician Partnerships - The company reports a high retention rate among physician partners, indicating strong relationships and engagement in driving improved economics [59][59] - There is ongoing demand for value-based care partnerships, despite macroeconomic challenges [62][62] Future Expectations - The company is optimistic about its positioning for 2026 and beyond, with plans to return to growth once a solid foundation is established [62][62] - Agilon is focused on executing strategies in 2025 that are expected to drive superior value in 2026 [77][77] Additional Important Insights - The regulatory environment is dynamic, and the company must remain nimble to adapt to changes, such as those in the ACO REACH program [20][20] - The discussions with payer partners have been constructive, with a focus on joint value creation and reducing volatility in contracts [36][36] - The company is working on improving cash and liquidity management, which is crucial for its operational model [37][37] This summary encapsulates the key points discussed during the Agilon Health FY Conference Call, highlighting the company's strategic focus, market dynamics, and financial outlook.

Core Insights - Humana Inc. is valued at a market cap of $34.2 billion and focuses on managed care services through health insurance offerings [1] - The company is set to announce its fiscal Q3 earnings for 2025 on November 5, 2025 [1] Financial Performance - Analysts expect Humana to report a profit of $2.91 per share for Q3 2025, a decrease of 30.1% from $4.16 per share in the same quarter last year [2] - For fiscal 2025, the expected profit is $17.07 per share, reflecting a 5.3% increase from $16.21 per share in fiscal 2024, but a decline of 20.9% year-over-year to $13.51 in fiscal 2026 [3] Stock Performance - Over the past 52 weeks, Humana's shares have increased by 13.3%, underperforming the S&P 500 Index's return of 15.1% but outperforming the Health Care Select Sector SPDR Fund's decline of 4.1% [4] - Following a strategic collaboration announcement with Providence, Humana's shares surged by 3.3% and then by another 3.9% in the subsequent trading session [5] Analyst Ratings - Wall Street analysts have a "Moderate Buy" rating for Humana, with 26 analysts covering the stock: six recommend "Strong Buy," two "Moderate Buy," 17 "Hold," and one "Strong Sell" [6] - The current trading price is above the mean price target of $292.42, with a Street-high price target of $347 indicating a potential 17.5% premium [6]

Core Insights - Counterpart Health's technology platform has achieved top-tier HEDIS results for Clover Health's Medicare Advantage plans, marking its continued success in the industry [1][2] - Clover Health has been recognized as the 1 performing PPO plan in the U.S. for HEDIS clinical quality measures for plans with over 2,000 members, showcasing the effectiveness of Counterpart's AI-driven platform [2] - The company is now offering its HEDIS excellence platform to third-party partners, aiming to enhance quality outcomes across a broader network [3] Company Overview - Counterpart Health, a subsidiary of Clover Health Investments, focuses on AI-powered physician enablement to transform care delivery and improve patient outcomes [4] - The flagship software, Counterpart Assistant, provides insights for managing chronic conditions and delivering high-quality care, extending its benefits beyond Clover Health's Medicare Advantage plan [4] Technology and Methodology - The HEDIS excellence flywheel utilized by Counterpart Health consistently delivers superior results for Clover's Medicare Advantage population, particularly in areas like colorectal cancer screening and diabetic eye exams [2][5] - The platform employs advanced technologies such as natural language processing (NLP) and large language models (LLM) to enhance care coordination and close documentation gaps [5]

Industry Overview - The U.S. healthcare services market is projected to grow from $8.77 trillion in 2024 to $9.25 trillion in 2025, driven by telehealth, digital health, workforce shortages, and changes in reimbursement models [1] - CVS Health and Elevance Health are major players in this competitive market, each with extensive reach and diversified services [1][2] CVS Health Analysis - CVS Health, valued at $90.32 billion, is experiencing revenue growth across all operating segments, with a focus on restoring Aetna to target margins through organizational realignment and technology enhancements [2][3] - The company is enhancing its pharmacy services by acquiring certain Rite Aid pharmacies and implementing a new pharmacy model, CostVantage, to address reimbursement pressures [6][7] - CVS is investing $20 billion over the next decade in digital health initiatives, aiming for $500 million in cost savings in 2025 [7] - The company has a strong cash flow generation and is focused on improving financial performance in its Health Care Delivery segment [4][7] Elevance Health Analysis - Elevance Health, with a market cap of $70.71 billion, is facing challenges due to shifts in Medicaid and ACA membership, leading to increased medical costs and a downward revision of its 2025 EPS outlook to $30 [2][8] - The company closed Q2 2025 with 45.6 million medical members, a decrease of approximately 200,000, and a consolidated benefit expense ratio of 88.9%, up 260 basis points from the previous year [10][13] - Elevance is showing strength in its Medicare Advantage portfolio and is working to stabilize trends in high-cost areas through streamlined processes and AI-enabled tools [11][12] Financial Performance and Projections - CVS Health's EPS for 2025 is projected to grow by 16.6% to $6.32, with estimates trending upward [20][21] - In contrast, Elevance Health's EPS estimate for 2025 is $30.15, reflecting an 8.8% decrease, with estimates having declined by 12.4% in the last 90 days [22] - Year-to-date, CVS shares have increased by 59.4%, while Elevance shares have decreased by 15.9% [16] Conclusion - CVS Health is positioned for long-term growth with its digital investments and restructuring efforts, while Elevance Health faces challenges in the ACA and Medicaid markets, making CVS the stronger investment option [22][23]

Core Insights - The new whitepaper from Counterpart Health demonstrates that a relationship with a primary care physician (PCP) using Counterpart Assistant is linked to improved management of Chronic Obstructive Pulmonary Disease (COPD), including more frequent diagnoses, increased specialty care, and significant reductions in hospitalizations and readmissions [2][4][5]. Group 1: Study Findings - The study indicates that COPD patients under the care of a PCP using Counterpart Assistant experienced a 15% lower average number of all-cause hospitalizations [8]. - There was an 18% reduction in the average number of 30-day readmissions for COPD patients attributed to PCPs utilizing Counterpart Assistant [8]. - New members with no prior COPD diagnosis who joined a Clover Medicare Advantage plan were 75% more likely to be diagnosed with COPD within their first year when cared for by a PCP using Counterpart Assistant [8]. Group 2: Technology Impact - Counterpart Assistant synthesizes over 100 real-time data streams with evidence-based guidelines to provide actionable recommendations, enhancing the ability of clinicians to manage COPD effectively [4]. - The whitepaper is the fifth retrospective analysis measuring the clinical impact of Counterpart Assistant on chronic disease management, building on previous studies related to heart failure, diabetes, and chronic kidney disease [5][7]. - The technology has shown positive correlations with improved patient care across various chronic conditions, reinforcing its role in proactive management of high-risk diseases [4][5].